Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Gains from Investment Securities (2016 - 2024)

Historic Gains from Investment Securities for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Q4 2024 value amounting to $11.7 million.

  • Syndax Pharmaceuticals' Gains from Investment Securities rose 938.92% to $11.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $11.7 million, marking a year-over-year increase of 938.92%. This contributed to the annual value of $11.7 million for FY2024, which is 938.92% up from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Gains from Investment Securities of $11.7 million as of Q4 2024, which was up 938.92% from $10.7 million recorded in Q4 2023.
  • Syndax Pharmaceuticals' 5-year Gains from Investment Securities high stood at $17.0 million for Q4 2022, and its period low was -$3000.0 during Q3 2020.
  • Moreover, its 5-year median value for Gains from Investment Securities was $1.1 million (2020), whereas its average is $4.2 million.
  • Within the past 5 years, the most significant YoY rise in Syndax Pharmaceuticals' Gains from Investment Securities was 6446363.64% (2020), while the steepest drop was 15000.0% (2020).
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' Gains from Investment Securities stood at $7.1 million in 2020, then surged by 42.2% to $10.1 million in 2021, then surged by 68.33% to $17.0 million in 2022, then tumbled by 37.15% to $10.7 million in 2023, then grew by 9.39% to $11.7 million in 2024.
  • Its last three reported values are $11.7 million in Q4 2024, $10.7 million for Q4 2023, and $308550.0 during Q3 2023.